Abstract:Background Proton pump inhibitors (PPIs) are usually prescribed to patients undergoing dual antiplatelet therapy to decrease the risk of gastrointestinal bleeding. However, the proportion of patients increased incidence of major adverse cardiovascular event because of interaction of PPIs and clopidogrel. The aim of the study was to assess the effect of omeprazole and pantoprazole on platelet reactivity in acute coronary syndrome patients receiving clopidogrel. Method From October 2012 to September 2013, a total of 620 consecutive acute coronary syndrome patients from Shenyang General Hospital were enrolled. All patients received clopidogrel loading dose 300 mg and aspirin 300 mg. Patients were randomised to two groups by the ratio of 1:1 and received routine dual anti-platelet treatment. The omeprazole group (aspirin 300 mg/d and clopidogrel 75 mg/d and omeprazole 20 mg/d, n = 310). The pantoprazole group (aspirin 300 mg/d and clopidogrel 75 mg/d and pantoprazole 20 mg/d, n = 310). The reversion rate of ADP which was defined as 20 μmol/L adenosine diphosphate induced platelet aggregation (by LTA) (on admission, three days and 30 days after dual antiplatelet therapy) and clinical events (stent thrombosis, MACEs, which included cardiac death, myocardial infarction or ischaemic symptoms driven target vessel revascularisation, all-cause death, TIMI) were observed. Result All groups were generally well balanced with regard to baseline demographic, clinical, and proced-ural characteristics. There were no different on platelet response to clopidogrel at three days (52.8% ± 19.3% vs 50.2% ± 19.3%, respectively, p = 0.384) and 30 days (49.9% ± 14.9% vs 49.1% ± 14.7%, respectively, p = 0.559) between omeprazole group and pantoprazole group. 1 stent thrombosis in the omeprazole group and 0 stent thrombosis in pantoprazole group (p = 0.219). 2 patients in omeprazole group were suffered from MACE (0.6%), and 3 patients in pantoprazole group (0.97%, p = 0.359). In addition, there were no major or minor bleeding in the two groups, the minimal bleeding in omeprazole and pantoprazole groups were no significantly difference (2.1% vs 2.8%, respectively, p = 0.235). There was no significantly association between the two groups for all-cause death (p = 0.687), and 1 patient died due to the traumatic brain injury in the omeprazole group. Conclusion These results suggest that the drug interaction between PPIs (omeprazole and pantoprazole)and clopidogrel does not result in ADP induced platelet aggregation. There was no apparent clinical events interaction between clopidogrel and omeprazole and pantoprazole in patients who received dual antiplatelet therapy. The clinic impact of this strategy needs to be proved by long term follow-up outcome studies.

Impact of pantoprazole on clopidogrel's anti-platelet effect in patients with acute coronary syndrome

ASSA14-03-35 Effects of Omeprazole and Pantoprazole on Platelet Function in Acute Coronary Syndrome Patients Receiving Clopidogrel: A Single-centre Prospective Randomised Controlled Clinical Trials

[Effects of Proton Pump Inhibitors on In-Stent Restenosis in Patients Receiving Clopidogrel: a Retrospective Analysis].

Influence of proton pump inhibitor esomeprazole on anti-platelet effect of clopidogrel

Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention.

The Influence of Omeprazole on the Anti-Platelet Action of Clopidogrel with Aspirin

[Impact of Statins on Clopidogrel Platelet Inhibition in Patients with Acute Coronary Syndrome or Stable Angina].

Progress in Interaction Between Clopidogrel and Proton Pump Inhibitors

Effect of Clopidogrel on Aspirin Resistance in Acute Coronary Syndrome Patients

Effects of treatment with clopidogrel with or without proton pump inhibitor omeprazole on the risk of ischemic stroke: a nationwide cohort study

[Impact of Proton Pump Inhibitor Omeprazole on the Antiplatelet Effect of Clopidogrel in Individuals with Various CYP2C19*2 Genotypes].

[The Antiplatelet Effect of Clopidogrel is Not Attenuated by Statin Treatment in Patients with Acute Coronary Syndromes Undergone Coronary Stenting].

A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients

Safety of Rebeprazole in Acute Coronary Syndrome Patients with Dual Anti-platelet Therapy after Percutaneous Coronary Intervention

Pharmacodynamic Impacts of Proton Pump Inhibitors on the Efficacy of Clopidogrel in Vivo—A Systematic Review

Pretreatment with Proton Pump Inhibitor Increases Sensitivity of Human Gastric Adenocarcinoma Cell Line to Antitumor Drugs

Insight of drug interaction between proton pump inhibitors and clopidogrel

Clinical analysis of clopidogrel resistance in patients with coronary heart disease after percutaneous coronary intervention

Angiotensin-Converting Enzyme Inhibitors' Influence on Antiplatelet Therapy of Clopidogrel in ACS.

Effect of Esomeprazole Versus Famotidine on Platelet Inhibition by Clopidogrel: A Double-Blind, Randomized Trial

Impact of Proton-pump Inhibitors on the Pharmacodynamic Effect and Clinical Outcomes in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: A Propensity Score Analysis